Literature DB >> 19800369

Antiviral evaluation of octadecyloxyethyl esters of (S)-3-hydroxy-2-(phosphonomethoxy)propyl nucleosides against herpesviruses and orthopoxviruses.

Nadejda Valiaeva1, Mark N Prichard, R Mark Buller, James R Beadle, Caroll B Hartline, Kathy A Keith, Jill Schriewer, Julissa Trahan, Karl Y Hostetler.   

Abstract

Our previous studies showed that esterification of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine (HPMPA) or 1-(S)-[3-hydroxy-2-(phosphonomethoxy)-propyl]cytosine (HPMPC) with alkoxyalkyl groups such as hexadecyloxypropyl (HDP) or octadecyloxyethyl (ODE) resulted in large increases in antiviral activity and oral bioavailability. The HDP and ODE esters of HPMPA were shown to be active in cells infected with human immunodeficiency virus, type 1 (HIV-1), while HPMPA itself was virtually inactive. To explore this approach in greater detail, we synthesized four new compounds in this series, the ODE esters of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)-propyl]guanine (HPMPG), 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]thymine (HPMPT), 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2-amino-6-cyclopropylaminopurine (HPMP-cPrDAP) and evaluated their antiviral activity against herpes simplex virus, type 1 (HSV-1), human cytomegalovirus (HCMV), and vaccinia, cowpox and ectromelia. Against HSV-1, subnanomolar EC(50) values were observed with ODE-HPMPA and ODE-HPMPC while ODE-HPMPG had intermediate antiviral activity with an EC(50) of 40 nM. In HFF cells infected with HCMV, the lowest EC(50) values were observed with ODE-HPMPC, 0.9 nM. ODE-HPMPA was highly active with an EC(50) of 3 nM, while ODE-HPMPG and ODE-HPMPDAP were also highly active with EC(50)s of 22 and 77 nM, respectively. Against vaccinia and cowpox viruses, ODE-HPMPG and ODE-HPMPDAP were the most active and selective compounds with EC(50) values of 20-60 nM and selectivity index values of 600-3500. ODE-HPMPG was also active against ectromelia virus with an EC(50) value of 410 nM and a selectivity index value of 166. ODE-HPMPG and ODE-HPMPDAP are proposed for further preclinical evaluation as possible candidates for treatment of HSV, HCMV or orthopoxvirus diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19800369      PMCID: PMC2787864          DOI: 10.1016/j.antiviral.2009.09.012

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  18 in total

1.  ELVIRA HSV, a yield reduction assay for rapid herpes simplex virus susceptibility testing.

Authors:  Ruzena Stránská; Rob Schuurman; David R Scholl; Joseph A Jollick; Carl J Shaw; Caroline Loef; Merjo Polman; Anton M van Loon
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

2.  Kinetics of ectromelia virus (mousepox) transmission and clinical response in C57BL/6j, BALB/cByj and AKR/J inbred mice.

Authors:  G D Wallace; R M Buller
Journal:  Lab Anim Sci       Date:  1985-02

3.  Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro.

Authors:  James R Beadle; Caroll Hartline; Kathy A Aldern; Natalie Rodriguez; Emma Harden; Earl R Kern; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

4.  Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.

Authors:  Mark N Prichard; Caroll B Hartline; Emma A Harden; Shannon L Daily; James R Beadle; Nadejda Valiaeva; Earl R Kern; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

5.  Restricted replication of ectromelia virus in cell culture correlates with mutations in virus-encoded host range gene.

Authors:  W Chen; R Drillien; D Spehner; R M Buller
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

6.  Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model.

Authors:  R Mark Buller; Gelita Owens; Jill Schriewer; Lora Melman; James R Beadle; Karl Y Hostetler
Journal:  Virology       Date:  2004-01-20       Impact factor: 3.616

7.  Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine.

Authors:  J Balzarini; A Holy; J Jindrich; L Naesens; R Snoeck; D Schols; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 8.  Chemotherapy of the acquired immune deficiency syndrome (AIDS): acyclic nucleoside phosphonate analogues.

Authors:  E De Clercq
Journal:  Int J Immunopharmacol       Date:  1991

9.  Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines.

Authors:  E De Clercq; T Sakuma; M Baba; R Pauwels; J Balzarini; I Rosenberg; A Holý
Journal:  Antiviral Res       Date:  1987-12       Impact factor: 5.970

Review 10.  Phosphonomethoxyalkyl analogs of nucleotides.

Authors:  Antonín Holy
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

View more
  7 in total

Review 1.  The search for new therapies for human cytomegalovirus infections.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Virus Res       Date:  2010-11-21       Impact factor: 3.303

2.  Inhibition of HIV-1 by octadecyloxyethyl esters of (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] nucleosides and evaluation of their mechanism of action.

Authors:  Wendy C Magee; Nadejda Valiaeva; James R Beadle; Douglas D Richman; Karl Y Hostetler; David H Evans
Journal:  Antimicrob Agents Chemother       Date:  2011-09-06       Impact factor: 5.191

Review 3.  Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects.

Authors:  Marcela Krečmerová; Pavel Majer; Rana Rais; Barbara S Slusher
Journal:  Front Chem       Date:  2022-05-20       Impact factor: 5.545

4.  Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.

Authors:  Sanaa S Botros; Samia William; James R Beadle; Nadejda Valiaeva; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

Review 5.  Advance of structural modification of nucleosides scaffold.

Authors:  Xia Lin; Chunxian Liang; Lianjia Zou; Yanchun Yin; Jianyi Wang; Dandan Chen; Weisen Lan
Journal:  Eur J Med Chem       Date:  2021-01-30       Impact factor: 6.514

6.  Transdermal delivery and cutaneous targeting of antivirals using a penetration enhancer and lysolipid prodrugs.

Authors:  Denisa Diblíková; Monika Kopečná; Barbora Školová; Marcela Krečmerová; Jaroslav Roh; Alexandr Hrabálek; Kateřina Vávrová
Journal:  Pharm Res       Date:  2013-11-22       Impact factor: 4.580

7.  Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety.

Authors:  Tomáš Tichý; Graciela Andrei; Robert Snoeck; Jan Balzarini; Martin Dračínský; Marcela Krečmerová
Journal:  Eur J Med Chem       Date:  2012-07-24       Impact factor: 6.514

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.